Dupixent 300 MG/2 ML pen 2ML
Ended Awarded
- Contract number
- SPE2DB25FQK85
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $22,112
Award facts
- Contract value 100% obligated
- $22,112.31 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injections with a ceiling value of $22,112.31. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by April 28, 2025. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor supporting federal medical procurement needs across military and veteran healthcare systems.
This delivery order exemplifies AmerisourceBergen's role as a prime pharmaceutical vendor for the DLA Medical Supply Chain, supplying specialty medications and healthcare products to support military medical requirements. Dupixent is a biologic treatment used for conditions such as atopic dermatitis, asthma, and eosinophilic conditions, representing the type of specialty pharmaceutical products encompassed within the company's broader federal contract portfolio. The firm fixed pricing structure and standardized delivery terms reflect the efficient procurement processes established under the underlying IDC vehicle, enabling the DLA to rapidly fulfill critical medication needs for Defense Health Agency customers and other government healthcare systems.
Quick answers
Who was awarded contract SPE2DB25FQK85?
SPE2DB25FQK85 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on April 25, 2025.
How much is contract SPE2DB25FQK85 worth?
The government has obligated $22,112 on SPE2DB25FQK85.
Is contract SPE2DB25FQK85 an order under another contract?
Yes. SPE2DB25FQK85 is a delivery order under SPE2DB22D3004, an indefinite delivery contract.
Was contract SPE2DB25FQK85 competed?
The extent of competition for SPE2DB25FQK85 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award